# Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

> **NCT02009865** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 379 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Epanova
- **DRUG:** Olive Oil

## Key facts

- **NCT ID:** NCT02009865
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-16
- **Primary completion:** 2014-12-23
- **Final completion:** 2014-12-23
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2019-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009865, "Epanova® for Lowering Very High Triglycerides II (EVOLVE II)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02009865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*